XenoPort to Release First Quarter Financial Results on May 5, 2016
April 26 2016 - 1:30PM
Business Wire
XenoPort, Inc. (Nasdaq: XNPT) announced today that it will
release its first quarter financial results on May 5, 2016 at
approximately 4:30 p.m. Eastern Time. The company will host a
conference call at 5:00 p.m. Eastern Time that same day to provide
a summary of its financial results and general business updates. A
replay of the call will be available for one week following the
event.
To access the conference call via the Internet, go to
www.XenoPort.com. Please join the call at least 15 minutes prior to
the start to ensure time for any software downloads that may be
required.
To access the live conference call via phone, dial
1-888-275-3514. International callers may access the live call by
dialing 706-679-1417. The reference number to enter the call is
77273079.
The replay of the conference call may be accessed that same day
after 8:00 p.m. Eastern Time, via the Internet, at
www.XenoPort.com, or via phone at 1-855-859-2056 for domestic
callers, or 404-537-3406 for international callers. The reference
number to enter the replay of the call is 77273079.
About XenoPort
XenoPort, Inc. is a biopharmaceutical company focused on
commercializing HORIZANT® (gabapentin enacarbil) Extended-Release
Tablets in the United States. XenoPort has entered into an
agreement with the National Institute on Alcohol Abuse and
Alcoholism (NIAAA) under which the NIAAA has initiated a clinical
trial evaluating gabapentin enacarbil as a potential treatment for
patients with alcohol use disorder. REGNITE® (gabapentin enacarbil)
Extended-Release Tablets is being marketed in Japan by Astellas
Pharma Inc. XenoPort has granted exclusive world-wide rights for
the development and commercialization of its clinical-stage oral
product candidate, arbaclofen placarbil, to Indivior UK Ltd. for
all indications. Pending review by the U.S. Government under the
Hart-Scott-Rodino Antitrust Improvements Act, XenoPort has also
granted U.S. rights for the development and commercialization of
its clinical-stage oral product candidate, XP23829, to Dr. Reddy’s
Laboratories. XenoPort developed and owns exclusive worldwide
rights to XP21279, a prodrug of levodopa that is a potential
treatment for patients with idiopathic Parkinson's disease.
HORIZANT, REGNITE and XENOPORT are registered trademarks of
XenoPort, Inc.
XNPT2F
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160426006526/en/
XenoPort, Inc.Jackie Cossmon, 408-616-7295ir@XenoPort.com
Xenoport, Inc. (NASDAQ:XNPT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Xenoport, Inc. (NASDAQ:XNPT)
Historical Stock Chart
From Sep 2023 to Sep 2024